Cancer Genetic Editing: New Method Reveals Tumor Activity & Potential Targets

The way cancer cells rewrite genetic instructions to fuel tumor growth is coming into sharper focus, thanks to a recent method for directly measuring this process. Researchers have identified hundreds of potential targets for future therapies by analyzing how tumors systematically reorganize their genetic activity. This perform, published in Nature Communications, offers a clearer picture of the complex mechanisms driving cancer progression and could pave the way for more effective treatments.

How Cancer Cells Alter Genetic Instructions

At the core of life, cells leverage genetic instructions to produce the proteins necessary for their function. Cancer arises from defects in these genes, but the behavior of a tumor cell isn’t solely determined by the flawed genes themselves. It’s also profoundly influenced by how those genetic instructions are modified before they’re translated into proteins. This modification process, known as splicing, is now the focus of intense research.

Splicing involves copying genetic instructions from DNA into RNA, which acts as a temporary message. Before this message is used to create proteins, the cell removes certain segments and joins the remaining pieces together. This editing process allows a single gene to generate different messages, leading to the production of various proteins – a crucial mechanism for the complexity of living organisms. Most cancers disrupt this splicing process, altering how these messages are assembled.

Tumors exploit this strategy to produce protein variants that promote rapid cell growth, help evade the immune system, or contribute to resistance to treatment. Understanding these alterations is key to developing targeted therapies.

A New Method for Measuring Splicing Changes

Traditionally, researchers have focused on the molecules responsible for carrying out the splicing process, known as splicing factors. However, the activity of these molecules can be influenced by hidden mechanisms – proteins can be degraded, chemically modified, or mutated without apparent changes in their levels. This can create an incomplete understanding of how genetic editing functions.

To overcome this limitation, a team at the Center for Genomic Regulation (CRG) in Barcelona, in collaboration with Columbia University, took a different approach. Instead of measuring the splicing factors themselves, they directly analyzed the changes occurring in the RNA messages. They adapted an existing technology called VIPER (Versatile In-situ Partitioning and Editing Reporter) to identify which segments of RNA messages are retained and which are eliminated during splicing. CRG explains that the resulting patterns act as a “fingerprint” of the RNA messages, revealing which editing mechanisms were active, regardless of how the involved molecules are regulated.

This method can be applied to data obtained through RNA sequencing, a widely used genetic analysis technique. This means the technique can be used to analyze thousands of existing samples without requiring additional experiments.

Analyzing Thousands of Tumors

The researchers applied the VIPER method to approximately 10,000 tumor biopsies from 14 different types of cancer, using data from The Cancer Genome Atlas, a publicly available database. For each tumor sample, they also analyzed corresponding healthy tissue for comparison. The analysis revealed two major programs of cellular editing that repeatedly appeared across all cancer types studied.

One program acts as an accelerator, becoming more active in tumors and associated with a less favorable prognosis for patients. The other functions as a brake, with its activity decreasing in cancer and linked to better survival rates. This discovery suggests that, despite their diversity, different types of cancer may employ common strategies for reorganizing genetic editing processes – strategies that have remained difficult to observe in studies focused solely on genes.

Identifying Potential Therapeutic Targets

When the researchers analyzed biological factors that could influence the balance of these editing programs, they identified approximately 100 candidate molecules that could be regulated to restore balance to the genetic editing mechanisms within cells. Among the most prominent was the gene FUS, known for its role in some neurological conditions. While not extensively investigated in cancer research, the strong signal identified in the analysis suggests it could be a relevant subject for further study.

The findings, as reported by Washington University School of Medicine, underscore the critical role of proteins in cancer development. Understanding how these proteins operate within cancer cells opens the door to new therapies that could block key proteins driving cancer growth or trigger immune responses to abnormal proteins created by cancer cells.

Beyond Cancer: Potential Applications in Other Diseases

The researchers believe this method has applications beyond cancer. Since the technique analyzes the result of genetic editing, not the specific cause, it could be used to study diseases where cells modify how they assemble their genetic instructions, including neurological disorders and immune system diseases.

What Comes Next: Refining Targets and Clinical Trials

The identification of these potential therapeutic targets is just the first step. Further research is needed to validate these targets and develop drugs that can effectively modulate their activity. This will involve laboratory studies to confirm the role of these molecules in cancer progression, followed by preclinical trials in animal models. If these studies are successful, clinical trials in humans will be necessary to assess the safety and efficacy of new therapies. The National Cancer Institute (NIH) is currently funding the Clinical Proteomic Tumor Analysis Consortium, which is investigating key proteins driving cancer and how they’re regulated, providing a framework for future research in this area. Recent reviews of protein biomarkers in oncology highlight the growing importance of this field for early detection, treatment response prediction, and personalized medicine.